Narrative review with three cases reports neurosensory recovery after peptide-based care for nerve injury
A narrative review of regenerative peptides including BPC-157 presents three uncontrolled clinical cases of inferior alveolar nerve injury managed with peptides, dexamethasone and local anesthetic; the authors report neurosensory recovery but state causality cannot be established.
Frontiers in oral health · 2026 · Case report · n=3 · Human · Published October 16, 2026
This page reports what published studies found. It is not medical advice, no provider-patient relationship is created by reading it, and nothing here is a recommendation to use any compound. Talk with a licensed clinician about your own situation. Read the full disclaimer.
What the study did
This is a human case report paired with a narrative review, describing three illustrative clinical cases of inferior alveolar nerve (IAN) injury. The authors describe the cases as hypothesis-generating and managed with what they call a multimodal approach.
The review portion analyzes what the authors term the biological rationale for regenerative peptides as potential adjuncts in peripheral nerve repair, naming BPC-157, thymosin β 4 derivatives (TB-500) and ARA-290 among the agents discussed.
What it reported
The authors write that experimental evidence suggests these peptides may affect biological pathways implicated in peripheral nerve repair, including inflammation regulation, cytoprotection, angiogenic signaling, extracellular matrix remodeling, Schwann cell biology and axonal regeneration. They immediately qualify that these processes have been demonstrated mainly in preclinical models and have not been directly established in patients with IAN injury.
The three cases, treated with a method incorporating peptide agents, dexamethasone and local anesthetic, showed neurosensory recovery during follow-up as described by the authors. The abstract also states that a phase-based intervention framework is proposed on the basis of these observations.
Reported dosing
The abstract does not report any dosing regimen, route, or treatment duration for BPC-157 or for the other agents named. It states instead that peptide-based interventions remain investigational, with unresolved questions concerning safety, delivery, optimal dosing, and long-term outcomes.
Limitations
The authors state the central limitation themselves: owing to the uncontrolled nature of these observations, spontaneous recovery and other confounding factors cannot be excluded, and causality cannot be established. With three cases, no control group, and no comparison arm described, the report cannot separate any treatment effect from natural recovery.
Peptides were given alongside dexamethasone and local anesthetic, so no individual component can be isolated. The mechanisms discussed come from preclinical models rather than from patients with this injury. The authors conclude that rigorous, controlled clinical trials and standardized outcome measures are required to validate efficacy.
Regulatory context
BPC-157, also called pentadecapeptide BPC 157, is not an FDA-approved drug for any use. This status comes from the site's regulatory review and not from this publication, which describes peptide-based interventions as investigational.
Claims and where they come from
Each statement below is followed by the passage of the source record it was checked against.
The authors describe the three clinical cases as hypothesis-generating and managed with a multimodal approach.
“presents three hypothesis-generating clinical cases managed using a multimodal approach”
The peptide mechanisms discussed come mainly from preclinical models, not from patients with this injury.
“these processes have been demonstrated mainly in preclinical models and have not been directly established in patients with IAN injury”
The three cases received peptide agents together with dexamethasone and local anesthetic, and the authors report neurosensory recovery during follow-up.
“Three illustrative clinical cases treated with a multimodal method incorporating peptide agents, dexamethasone, and local anesthetic showed neurosensory recovery during follow-up.”
The authors state that causality cannot be established from these uncontrolled observations.
“owing to the uncontrolled nature of these observations, spontaneous recovery and other confounding factors cannot be excluded, and causality cannot be established”
The authors describe dosing as an unresolved question and call peptide-based interventions investigational.
“peptide-based interventions remain investigational, with unresolved questions concerning safety, delivery, optimal dosing, and long-term outcomes”
The authors call for controlled trials and standardized outcome measures before efficacy can be claimed.
“Rigorous, controlled clinical trials and standardized outcome measures are required to validate efficacy”
Common questions
Was there a control group?
No. The authors state that the observations were uncontrolled and that spontaneous recovery and other confounding factors cannot be excluded.
Does the abstract say how much BPC-157 was given?
No. The abstract reports no doses, routes, or schedules, and lists optimal dosing among the unresolved questions.
Was BPC-157 the only agent used?
No. The abstract states the cases were treated with a multimodal method incorporating peptide agents, dexamethasone, and local anesthetic.
What do the authors say is needed next?
They write that rigorous, controlled clinical trials and standardized outcome measures are required to validate efficacy and define the role of these agents in management of IAN injury.
Source
- 1.Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases — Frontiers in oral health (2026)Case reporthumann=3PMID 42876687DOI 10.3389/froh.2026.1907109